The hypocretin/orexin receptor: Therapeutic prospective in sleep disorders

Expert Opinion on Investigational Drugs

Volumn 16, Issue 11, 2007, Pages 1785-1797

  Nishino, Seiji ^a  

^a Sleep and Circadian Neurobiology Laboratory   (United States)

Author keywords

GPCR; Hypocretin; Hypocretin orexin; Narcolepsy; Neuropeptide; Sleep disorders

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (2 METHYLBENZOXANZOL 6 YL) 3 [1,5]NAPHTHYRIDIN 4 YLUREA; 1 (5,8 DIFLUOROQUINOLIN 4 YL) 3 (4 DIMETHYLAMINOPHENYL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; 1 (6,8 DIFLUORO 2 METHYLQUINOLIN 4 YL) 3 (4 DIMETHYLAMINOPHENYL)UREA; 1 [5(2 FLUROPHENYL) 2 METHYLTHIAZO 4 YL] 1 [2 (5 PHENYL[1,3,4]OXADIAZOL 2 YLMETHYL)PYRROLIDIN 1 YL]METHANONE; 2 [6,7 DIMETHOXY 1 [2 (4 TRIFLUOROMETHYLPHENYL)ETHYL] 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL] N METHYL 2 PHENYLACETAMIDE; 4 HYDROXYBUTYRIC ACID; ACT 078573; AMPHETAMINE; ARMODAFINIL; BENZODIAZEPINE; CARBANILAMIDE DERIVATIVE; CLOMIPRAMINE; DOXEPIN; FLURAZEPAM; GW 649868; IMIPRAMINE; ISOQUINOLINE DERIVATIVE; METHYLPHENIDATE; MODAFINIL; N ACYL 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLONE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; SB 410220; SB 674042; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLPIDEM; CENTRAL STIMULANT AGENT; G PROTEIN COUPLED RECEPTOR; HYPNOTIC SEDATIVE AGENT; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; OREXIN RECEPTORS; OREXINS; SIGNAL PEPTIDE;

CLINICAL TRIAL; DRUG DESIGN; DRUG INDUSTRY; ENDOCRINE DISEASE; HIGH THROUGHPUT SCREENING; HUMAN; INSOMNIA; NARCOLEPSY; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; SLEEP DISORDER; ANIMAL; CATAPLEXY; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; HYPNOTICS AND SEDATIVES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 36048958028     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.11.1785     Document Type: Review

References (78)

1. NISHINO S, SAKURAI T: The orexin/hypocretin system: its physiology and pathophysiology. In: Contemporary Clinical Neuroscience. Baghdoyan H (Ed.), Humana, Totowa, New Jersey, USA (2006).
2. NISHINO S: The hypocretin/orexin system in health and disease. Biol. Psychiany (2003) 54(2):87-95.
3. FUJIKI N, RIPLEY B, YOSHIDA Y, MIGNOT E, NISHINO S: Effects of IV and ICV hypocretin-1 (orcxin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep (2003) 6(8):953-959.
4. PERRY SJ, SCHWARTZ DA, MAKI RA: Pharmacology of Orexin/Hypocretin Peptides and Small Molecules, in the Orexin/Hypocrelin System: its Physiology and Pathophysiology, Nishino S, Sakurai T (Eds), Humana, Totowa, New Jersey, USA (2006):349-357.
5. BRISBARE-ROCH C, DINGEMANSE J, KOBERSTEIN R et al.: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. (2007) 13(2):150-155.
6. SAKURAI T, AMEMIYA A, ISHII M et al.: Orexins and orexin receptors: a family of hypothalamic neuropepeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 92:573-585.
7. DE LECEA L, KILDUFFTS, PEYRON C et al.: The hypocretins: hypothalamus-specific peptides with neuroexcicatory activity. Proc. Natl. Acad. Sci. USA (1998) 95:322-327.
8. KASTIN AJ, AKERSTROM V: Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. (1999) 289:219-223.
9. ZHU Y, MIWA Y, YAMANAKA A et al.: Orexin receptor type-1 couples exclusively to periussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J. Pharmacol. Sci. (2003) 92(3):259-266.
10. NANMOKU T, ISOBE K, SAKURAI T et al.: Effects of orexin on cultured porcine adrenal medullary and cortex cells. Regul. Pept. (2002) 104(1-3):125-130.
11. KARTERIS E, RANDEVA HS, GRAMMATOPOULOS DK, JAFFE RB, HILLHOUSE EW: Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals. J. Clin. Endocrinol. Metab. (2001) 86(9):4512-4519.
12. NISHINO S, OKURA M, MIGNOT E: Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med. Rev. (2000) 4(1):57-99.
13. BROUGHTON R, DUNHAM W, NEWMAN J et al.: Ambulatory 24 h sleep-wake monitoring in narcolepsy-cataplexy compared to matched control. Electroenceph. Clin. Neurophysiol. (1988) 70:473-481.
14. ALDRICH MS, CHERVIN RD, MALOW BA: Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep (1997) 20(8):620-629.
15. FUKUDA K, MIYASITA A, INUGAMI M, ISHIHARA K: High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep (1987) 10(3):279-286.
16. TAKEUCHI T, MIYASITA A, SASAKI Y, INUGAMI M, FUKUDA K: Isolated sleep paralysis elicited by sleep interruption. Sleep (1992) 15(3):217-225.
17. CHEMELLI RM, WILLIE JT, SINTON CM et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 98:437-451.
18. LIN L, FARACO J, LI R et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 98(3):365-376.
19. PEYRON C, FARACO J, ROGERS W et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. (2000) 6(9):991-997.
20. NISHINO S, RIPLEY B, OVEREEM S, LAMMERS GJ, MIGNOT E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 355(9197):39-40.
21. NISHINO S, KANBAYASHI T: Symptomatic narcolepsy, cataplexy and hypersomma, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med. Rev. (2005) 9(4):269-310.
22. RIPLEY B, FUJIKI N, OKURA M, MIGNOT E, NISHINO S: Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol. Dis. (2001) 8(3):525-534.
23. WILLIE JT, CHEMELLI RM, SINTON CM et al.: Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genecic dissection of non-REM and REM steep regulatory processes. Neuron (2003) 38(5):715-730.
24. LEE MG, HASSANI OK, JONES BE: Discharge ofidentified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. (2005) 25(28):6716-6720.
25. MILEYKOVSKIY BY, KIYASHCHENKO LI, SIEGEL JM: Behavioral correlates ofactivity in identified hypocretin/orexin neurons. Neuron (2005) 46(5):787-798.
26. HAGAN JJ, LESLIE RA, PATEL S et al.: Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. USA (1999) 96(19):10911-10916.
27. PIPER DC, UPTON N, SMITH MI, HUNTER AJ: The novel brain neuropepride, orexin-A, modulates the sleep-wake cycle of rats. Eur. J. Neurosci. (2000) 12(2):726-730.
28. FUJIKI N, YOSHIDA Y, RIPLEY B et al.: Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport (2001) 12(5):993-997.
29. YOSHIDA Y, FUJIKI N, NAKAJIMA T et al.: Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. (2001) 14(7):1075-1081.
30. ZHANG S, ZEITZER JM, YOSHIDA Y et al.: Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocrerin-1 release. Sleep (2004) 27(4):619-627.
31. MITLER MM, ALDRICH MS, KOOB GF, ZARCONE VP: Narcolepsy and its treatment with stimulants. Sleep (1994) 17(4):352-371.
32. NISHINO S, MIGNOT E: Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. (1997) 52(1):27-78.
33. BABCOCK DA, NARVER EL, DEMENT WC, MITLER MM: Effects of imipramine, chlorimipramine, and fluosetine on cataplexy in dogs. Pharmacol. Biochem. Behav. (1976) 5:599-602.
34. FOUTZ AS, DELASHAW JB, GUILLEMINAULT C, DEMENT WC: Monoaminergic mechanisms and experimental cataplexy. Ann. Neurol (1981) 10:369-376.
35. YAMANAKA A, BEUCKMANN CT, WILLIE JT et al.: Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron (2003) 38(5):701-713.
36. YAMANAKA A, TSUJINO N, FUNAHASHI H et al.: Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. (2002) 290(4):1237-1245.
37. KIYASHCHENKO LI, MILEYKOVSKIY BY, LAI YY, SIEGEL JM: Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J. Neurophysiol. (2001) 85(5):2008-2016.
38. NAMBU T, SAKURAI T, MIZUKAMI K et al.: Distribution of orexin neurons in the adult rat brain. Brain Res.(1999) 827:243-260.
39. PEYRON C,TIGHE DK, VAN DEN POL AN et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. (1998) 18(23):9996-10015.
40. HORVATH TL, PEYRON C, DIANO S et al.: Hypocretin (orexin) activation and synaptic innervation ofthe locus coeruleus noradrenergic system. J. Comp. Neurol. (1999) 415(2):145-159.
41. HARA J, B EUCKMANN CT, NAMBU T et al.: Generic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron (2001) 30(2):345-354.
42. MIEDA M, WILLIE JT, HARA J et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy, in mice. Proc. Natl. Acad. Sci. USA (2004) 101(13):4649-4654.
43. FUJIKI N, YOSHIDA Y, RIPLEY B, MIGNOT E, NISHINO S: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep (2003) 26(8):953-959.
44. PORTER RA, CHAN WN, COULTON S et al.: 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg. Med. Chem. Lett. (2001) 11(14):1907-1910.
45. SMART D, SABIDO-DAVID C, BROUGH SJ et al.: SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. (2001) 132(6):1179-1182.
46. BINGHAM MJ, CAI J, DEEHAN MR: Eating, sleeping and rewarding: orexin receptors and their antagonists. Curr. Opin. Drug Discov. Devel. (2006) 9(5):551-559.
47. CAI J, COOKE FE, SHERBORNE BS: Antagonists of the orexin receptors. Expert Opin. Ther. Patents (2006) 16(5):631-646.
48. SOFFIN EM, GILL CH, BROUGH SJ, JERMAN JC, DAVIES CH: Pharmacological characterisation of the orexin receptor subtype mediating postsynaptic excitation in the rat dorsal raphe nucleus. Neuropharmacology (2004) 46(8):1168-1176.
49. HAYNES AC, JACKSON B, CHAPMAN H et al.: A selective orexin-1 receptor antagonist reduces food consumption in male and Female rats. Regul. Pept. (2000) 96(1-2):45-51.
50. RODGERS RJ, HALFORD JC, NUNES DE SOUZA RL et al.: SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J. Neurosci. (2001) 13(7):1444-1452.
51. ISHII Y, BLUNDELL JE, HALFORD JC et al.: Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol. Behav. (2004) 81(1):129-140.
52. DUXON MS, STRETTON J, STARR K et al.: Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement. Psychopharmacology (Berl) (2001) 153(2):203-209.
53. KUSHIKATA T, HIROTA K, YOSHIDA H et al.: Orexinergic neurons and barbiturate anesthesia. Neuroscience (2003) 121(4):855-863.
54. HAYNES AC, CHAPMAN H, TAYLOR C et al.: Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ ob mice, Regul. Pept. (2002) 104(1-3):153-159.
55. MOBARAKEH JI, TAKAHASHI K, SAKURADA S et al.: Enhanced antinocicepcion by in tracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice. Peptides (2005) 26(5):767-777.
56. HIROTA K, KUSHIKATA T, KUDO M et al.: Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats. Brain Res. (2003) 98(1-2):143-150.
57. LANGMEAD CJ, JERMAN JC, BROUGH SJ et al.: Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. (2004) 141(2):340-346.
58. UPTON N, STRETTON J, DUXON MS et al.: Evidence that orexin-A-evoked grooming, but not water intake, in the rat is mediated by orexin-1 (OX1) receptor. Soc. Neuroscience. (2001) 27:320-321 (Abstract).
59. HIROSE M, EGASHIRA S, GOTO Y et al.: N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. (2003) 13(24):4497-4499.
60. MCATEE LC, SUTTON SW, RUDOLPH DA et al.: Novel Substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. (2004) 14(16):4225-4229.
61. OHAYON MM: Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev. (2002) 6(2):97-111.
62. OHAYON MM, PARTINEN M: Insomnia ind global sleep dissatisfaction in Finland. J. Sleep Res. (2002) 11(4):339-346.
63. MELLINGER GD, BALTER MB, UHLENHUTH EH: Insomnia and its treatment: prevelance and correlates. Arch. Gen. Psychiatry (1985) 42:225-232.
64. NISHINO S, MIGNOT E, DEMENT WC: Sedative-hypnotics. In: Textbook of Psychopharmacology. Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Press, Wishington, DC, USA (2004):651-684.
65. JOHNSON MW, SUESS PE, GRIFFITHS RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry (2006) 63(10):1149-1157.
66. CROSTON GF, OLSSON R, CURRIER EA et al.: Discovery of the first nonpeptide agonist of the GPR14/urotensin,sin-H receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino) ethyl)isochroman-1-one (AC-7954). J. Med. Chem. (2002) 45(23):4950-4953.
67. ZAVERI N: Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. (2003) 73(6):663-678.
68. SAAR K, MAZARATI AM, MAHLAPUU R et al.: Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. USA (2002) 99(10):7136-7141.
69. MIGNOT E, LAMMERS GJ, RIPLEY B et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersominas. Arch. Neurol. (2002) 59(10):1553-1562.
70. ARII J, KANBAYASHI T, TANABE Y et al.: CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology (2004) 63(12):2440-2442.
71. HONDA Y: Clinical features of narcolepsy: Japanese experience. In: HLA in Narcolepsy. Honda Y, Juji T (Eds), Springer-Verlag, New York, USA (1988):24-57.
72. NISHINO S, RIPLEY B, OVEREEM S et al.: Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. (2001) 50:381-388.
73. SAKURAI T: Roles of orexins in regulation of feeding and wakefulness. Neuroreport (2002) 13(8):987-995.
74. MARCUS JN, ASCHKENASI CJ, LEE CE et al.: Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. (2001) 435(1):6-25.
75. NISHINO S, MIGNOT E: CNS stimulants in sleep medicine: basic mechanisms and pharmacology. In: Principles and Practice of Sleep Medicine. (4th Edition), Kryger MH, Roth T, Dement WC (Eds), Elsvier Saunders, Philadelphia, USA (2005):468-498.
76. NISHINO S: Anticaraplectic medications. In: Narcolepsy and Hypersomnia. Bassetti C, Billiard M, Mignot E (Eds), Informa Healthcare USA, New York, USA (2007):531-546.
77. MIGNOT E, TAHERI S, NISHINO S: Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat. Neurosci. Suppl. (2002) 5:1-6.
78. SZABADI E: Drugs for sleep disorders: mechanisms and therapeutic prospects. Br. J. Clin. Pharmacol. (2006) 61(6):761-766.